No Carolina / NY / Florida
Ph: 561.316.3330

HomeACQUISITIONS and MERGERS

Category: ACQUISITIONS and MERGERS

Johnson & Johnson to Acquire...

The acquisition of Shockwave further extends Johnson & Johnson MedTech’s position in cardiovascular intervention and accelerates its shift into higher-growth markets.

Owen Mumford Acquires Empelvic

“The acquisition of Empelvic reinforces our commitment to comprehensive health solutions for intimate conditions,” said Adam Mumford, Director of Medical Devices at Owen Mumford. “By combining Owen Mumford's global expertise with Empelvic's innovative product, we aim to provide enhanced support and choices for individuals seeking pelvic health solutions.”

Johnson & Johnson to Acquire Shockwave Medical

The acquisition of Shockwave further extends Johnson & Johnson MedTech’s position in cardiovascular intervention and accelerates its shift into higher-growth markets.

NAMSA ® Acquires Syntactx to Enhance End-to-End CRO Development Solutions, Expanding Medical Device Clinical Research Capabilities and Expertise

“Syntactx is very proud to join NAMSA, a long-recognized industry leader in CRO medical device development and clinical research services,” stated Dr. Kenneth Ouriel, President and CEO of Syntactx.

Exact Sciences Completes Acquisition of Thrive Earlier Detection: Blood-Based Multi-Cancer Screening Becomes a Reality & Eventually the Standard of Care Notes CEO

Chairman and CEO Kevin Conroy said, "Bringing Thrive into the Exact Sciences family marks a giant leap toward blood-based, multi-cancer screening becoming a reality and eventually the standard of care.

Collagen Matrix Acquires Sunstar’s Degradable Solutions Division

Founded in 1999, Degradable Solutions AG, is headquartered in Schlieren, Switzerland, and has been part of the Sunstar Group since 2011.

United Therapeutics Announces Agreement To Acquire Priority Review Voucher

December 28, 2020 United Therapeutics Corporation announced today an agreement to acquire a Rare Pediatric Disease Priority Review Voucher (PRV), which it plans to use with a forthcoming New Drug Application with the U.S. Food and Drug Administration. United Therapeutics advises the PRV entitles the holder to designate an new drug application for priority review and provides for an expedited eight-month review, instead of the standard twelve-month review period. Following the close of the transaction, United Therapeutics intends to apply the...

Dalrada Financial Announces Acquisitions In Healthcare And Engineering

The acquisition of Pacific Stem Cells, LLC would further expand Dalrada Health's product and services offerings in the healthcare industry.

CompuGroup Medical Reports Successful Completion of Acquisition of eMDs in the US

"With eMDs, we are taking our US business to a new dimension. Know-how, products, and target markets excellently complement one another," said Frank Gotthardt, founder and CEO of CompuGroup Medical SE & Co. KGaA. The Group, with its headquarters in Germany, is one of the world's leading providers of eHealth solutions.

Orthopaedic and Spine Center of the Rockies and Front Range Orthopedics & Spine Enter Into Definitive Merger Agreement

December 19, 2020 Orthopaedic and Spine Center of the Rockies (OCR) and Front Range Orthopedics & Spine (FROC) are pleased to announce the companies have entered into a definitive merger agreement to merge FROC under the OCR umbrella, effective Jan. 1, 2021. This new partnership forms the largest privately owned fully vertically integrated orthopedic and spine medical group in Colorado, and one of the largest in the United States. FROC and OCR physicians have held high admiration for each other’s reputations, training,...

Philips to Acquire BioTelemetry, Inc.

“The acquisition of BioTelemetry fits perfectly with our strategy to be a leading provider of patient care management solutions for the hospital and the home,” said Frans van Houten, CEO of Royal Philips.

AstraZeneca to Acquire Alexion: Greater Scientific Presence In Immunology by Adding Alexion’s Innovative Complement-technology Platforms and Strong Pipeline

December 12, 2020 AstraZeneca announced today they have entered into a definitive agreement for AstraZeneca to acquire Alexion. Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share. Based on AstraZeneca's reference average ADR price of $54.14, this implies total consideration to Alexion shareholders of $39bn or $175 per share. The boards of directors of both...

By using this website you agree to accept Medical Device News Magazine Privacy Policy